The Medicines Service Advisory Committee (MSAC) appraises medical services, health technologies and/or programs proposed for public funding, and provides advice to Government about the level and quality of evidence relating to the comparative safety, clinical effectiveness, cost-effectiveness, and total cost of providing such services.
MSAC has released new draft guidelines for consultation. The Guidelines provide advice to applicants and assessment groups on the health technology assessment (HTA) methods used by Medical Services Advisory Committee (MSAC) to assess requests for public funding that fall within the remit of MSAC, e.g. Medicare Benefits Schedule (MBS) services, national screening programmes, blood products for the National Product List (NPL), and technologies which may be funded via other mechanisms.
The Department is interested in obtaining views and feedback from the general public and future users on the updated MSAC Guidelines.
More information about the guidelines and the review is available here. Submissions are due by 12 October.
The HSRAANZ would be interested to receive members' views on this issue and they can be submitted to email@example.com.